For US Healthcare Professionals only | Patients & Caregivers | Full Prescribing Information | Important Safety Information

The Gel Technology Difference

Mucoadhesive lubricating gel technology designed to increase contact time on the ocular surface to support penetration and drug delivery without BAK.^1-4

FACILITATES

low-dose bimatoprost penetration without BAK^1,5

DESIGNED TO INCREASE

contact time on the ocular surface, staying longer^1,2

APPLIES

with a unique patented gel formula that allows delivery as a drop^{1,3, 4}

Inactive ingredients: Carbomer gel (mucoadhesion and hydration), sodium acetate trihydrate (fluid consistency), polyethylene glycol 4000 (gel stabilization)^1,3,6

Patent: https://thea.com/en_WW/page/thea-our-r-d

Three-step diagram showing Zolymbus gel contacting the ocular surface and supporting prolonged residence time.

Preclinical data support drug delivery without the use of preservatives⁷

PRECLINICAL SAFETY

Preclinical in vitro chart comparing corneal penetration and ocular tissue exposure between preservative-free bimatoprost gel and comparator formulations.

Preclinical study methodology: Pigmented rabbits received a single topical dose of preservative-free bimatoprost 0.01% gel, bimatoprost 0.01%, or bimatoprost 0.03%. Ocular tissues were analyzed to assess pharmacokinetic parameters.⁷

AH=aqueous humor; BAK=benzalkonium chloride; ICB=iris ciliary body; PF=preservative-free.

INDICATIONS AND USAGE

ZOLYMBUS™ (bimatoprost ophthalmic gel) 0.01%, is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Known hypersensitivity to bimatoprost or any other ingredients in this product.

WARNINGS AND PRECAUTIONS

Bimatoprost may cause changes to pigmented tissues. Most frequently reported changes are increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as bimatoprost is administered. Iris pigmentation is likely to be permanent. Eyelid skin darkening and eyelash changes may be reversible.

Bimatoprost may cause gradual change to eyelashes including increased length, thickness, and number of lashes. These changes are usually reversible upon discontinuation of treatment.

Prostaglandin analogs, including bimatoprost, have been reported to cause intraocular inflammation. ZOLYMBUS should be used with caution in patients with active intraocular inflammation (e.g., iritis/uveitis) because inflammation may be exacerbated.

Macular edema, including cystoid macular edema, has been reported during treatment with bimatoprost ophthalmic products. ZOLYMBUS should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.
Contact lenses should be removed prior to the administration of ZOLYMBUS and may be reinserted 15 minutes after administration.

ADVERSE REACTIONS

Most common adverse reactions (≥10%) are conjunctival hyperemia (14%) and eye irritation (11%).

Please click here for the full Prescribing Information.

References: 1. Muñoz-Negrete FJ, Topouzis F, Oddone F, et al. Preservative-free bimatoprost 0.01% ophthalmic gel for glaucoma therapy: a phase III randomized clinical trial. J Glaucoma. 2024;33(6):422-430. 2. Miller-Ellis E, Peace JH, Day DG, et al. Safety and efficacy of a preservative-free bimatoprost 0.01% ophthalmic gel: results from a phase III controlled trial. J Glaucoma. 2025;34(11):880-887. 3. ZOLYMBUS [prescribing information]. Thea Pharma Inc; 2025. 4. Polzer H, Elena P, Senge J, inventors. Drippable ophthalmic bimatoprost gel. European patent EP3103439 (B1). August 7, 2019. 5. Thea data on file. 2022. Module 2.7.3 Summary of clinical efficacy. Study 301. 6. Thea data on file. 2026. Efficacy and safety of preservative-free bimatoprost gel 0.01% in patients with open-angle glaucoma (OAG) and ocular hypertension (OHT): phase III trial results. 7. Erb C, Topouzis F, Jayaram H, et al. Preclinical and clinical pharmacokinetics of a new preservative-free bimatoprost 0.01% ophthalmic gel to treat glaucoma and ocular hyptertension. J Ocul Pharmacol Ther. 2025;41(1):8-16.

ZOLYMBUS is a trademark of Laboratoires Théa.
Copyright ©2026 Thea Pharma Inc. All Rights Reserved. PRC-EN-3014-v2 08.2026

INDICATIONS AND USAGE

ZOLYMBUS™ (bimatoprost ophthalmic gel) 0.01%, is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Known hypersensitivity to bimatoprost or any other ingredients in this product.